1. Home
  2. CTMX vs EDAP Comparison

CTMX vs EDAP Comparison

Compare CTMX & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • EDAP
  • Stock Information
  • Founded
  • CTMX 2008
  • EDAP 1979
  • Country
  • CTMX United States
  • EDAP France
  • Employees
  • CTMX N/A
  • EDAP N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • CTMX Health Care
  • EDAP Health Care
  • Exchange
  • CTMX Nasdaq
  • EDAP Nasdaq
  • Market Cap
  • CTMX 62.3M
  • EDAP 81.6M
  • IPO Year
  • CTMX 2015
  • EDAP 1997
  • Fundamental
  • Price
  • CTMX $0.80
  • EDAP $2.86
  • Analyst Decision
  • CTMX Buy
  • EDAP Strong Buy
  • Analyst Count
  • CTMX 6
  • EDAP 1
  • Target Price
  • CTMX $5.77
  • EDAP $19.00
  • AVG Volume (30 Days)
  • CTMX 731.5K
  • EDAP 39.8K
  • Earning Date
  • CTMX 03-10-2025
  • EDAP 03-26-2025
  • Dividend Yield
  • CTMX N/A
  • EDAP N/A
  • EPS Growth
  • CTMX N/A
  • EDAP N/A
  • EPS
  • CTMX 0.16
  • EDAP N/A
  • Revenue
  • CTMX $126,617,000.00
  • EDAP $70,722,730.00
  • Revenue This Year
  • CTMX $22.55
  • EDAP $6.96
  • Revenue Next Year
  • CTMX N/A
  • EDAP $15.53
  • P/E Ratio
  • CTMX $4.93
  • EDAP N/A
  • Revenue Growth
  • CTMX 33.66
  • EDAP 12.17
  • 52 Week Low
  • CTMX $0.75
  • EDAP $2.00
  • 52 Week High
  • CTMX $5.85
  • EDAP $8.50
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 41.61
  • EDAP 73.01
  • Support Level
  • CTMX $0.75
  • EDAP $2.46
  • Resistance Level
  • CTMX $0.98
  • EDAP $2.69
  • Average True Range (ATR)
  • CTMX 0.06
  • EDAP 0.16
  • MACD
  • CTMX 0.00
  • EDAP 0.04
  • Stochastic Oscillator
  • CTMX 20.13
  • EDAP 94.44

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: